Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.42 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205594 | 0.92 | EGFR (0.48) | TSHRHTTALDH1A1RAB9ANPC1 | |
| SCHEMBL2152998 | 0.89 | EGFR (0.44) | HTTALDH1A1KDM4EGAAADORA2A | |
| SCHEMBL6833359 | 0.87 | PDE4A (0.47) | TSHRHTTALDH1A1RAB9AKDM4E | |
| SCHEMBL454627 | 0.85 | EGFR (0.47) | TSHRALDH1A1RAB9ANPC1KDM4E | |
| SCHEMBL19847491 | 0.82 | MAPT (0.45) | HTTALDH1A1KDM4EGAAADORA2A | |
| SCHEMBL19847501 | 0.80 | MAPT (0.44) | HTTALDH1A1KDM4EGAAADORA2A | |
| SCHEMBL3301303 | 0.80 | MGMT (0.49) | TSHRHTTALDH1A1RAB9ANPC1 | |
| SCHEMBL21896378 | 0.79 | CDK1 (0.48) | HTTALDH1A1NPC1KDM4EGAA | |
| SCHEMBL19978373 | 0.79 | ALDH1A1 (0.43) | TSHRHTTALDH1A1RAB9ANPC1 | |
| SCHEMBL431825 | 0.78 | CDK1 (0.61) | TSHRRAB9ANPC1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115136-A1 | PNA DIAGNOSTIC USE | PNA Patent Owners (a/k/a CIG) (US) | 2012-05-10 | — | — | US | disclosed |
| EP-1074559-B1 | Peptide nucleic acids | BUCHARDT OLE (DK) | 2011-07-06 | — | — | EP | disclosed |
| US-7378485-B2 | Peptide nucleic acids with polyamide-containing backbones | BUCHARDT OLE | 2008-05-27 | — | — | US | disclosed |
| US-20060160731-A1 | Peptide nucleic acids | BUCHARDT OLE | 2006-07-20 | — | — | US | disclosed |
| EP-1411063-B1 | Peptide nucleic acids | BUCHARDT OLE (DK) | 2006-07-19 | — | — | EP | disclosed |
| EP-0960121-B1 | PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY | BUCHARDT DORTE (DK) | 2005-11-30 | — | — | EP | disclosed |
| EP-1411063-A1 | Peptide nucleic acids | BUCHARDT, Ole (DK) | 2004-04-21 | — | — | EP | disclosed |
| US-20040059087-A1 | Peptide nucleic acids | BUCHARDT OLE (DK) | 2004-03-25 | — | — | US | disclosed |
| US-6710164-B1 | COMPRISING AT LEAST ONE C1-C8 ALKYLAMINE SIDE CHAIN | NIELSEN PETER E (DK) | 2004-03-23 | — | — | US | disclosed |
| US-6686442-B2 | PEPTIDE NUCLEIC ACID FOR USE IN VETERINARY MEDICINE | Neilsen, Peter E. (DK) | 2004-02-03 | — | — | US | disclosed |
| EP-1162206-A2 | Peptide nucleic acids | BUCHARDT, Ole (DK) | 2001-12-12 | — | — | EP | disclosed |
| EP-0586474-B1 | PEPTIDE NUCLEIC ACIDS | BUCHARDT OLE (DK) | 2001-09-12 | — | — | EP | disclosed |
| EP-1074559-A1 | Peptide nucleic acids | BUCHARDT, Ole (DK) | 2001-02-07 | — | — | EP | disclosed |
| EP-1003480-A1 | CONJUGATED PEPTIDE NUCLEIC ACIDS HAVING ENHANCED CELLULAR UPTAKE | NIELSEN, Peter Eigil (DK) | 2000-05-31 | — | — | EP | disclosed |
| EP-0960121-A1 | PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY | BUCHARDT, Dorte (DK) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998053801-A1 | CONJUGATED PEPTIDE NUCLEIC ACIDS HAVING ENHANCED CELLULAR UPTAKE | ISIS PHARMACEUTICALS, INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998003542-A1 | PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY | BUCHARDT, DORTE (DK) | 1998-01-29 | — | — | WO | disclosed |
| EP-0586618-B1 | THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES | BUCHARDT DORTE (DK) | 1997-07-16 | — | — | EP | disclosed |
| WO-1992020703-A1 | THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES | BUCHARDT OLE (DK) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992020702-A1 | PEPTIDE NUCLEIC ACIDS | BUCHARDT OLE (DK) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115136-A1 | PNA DIAGNOSTIC USE | RNASE1, NCL, PABPC4 | TSHR 2257/4885HTT 2104/4885ALDH1A1 2720/4885 |
| US-20060160731-A1 | Peptide nucleic acids | RNGTT, POLM, POLRMT | TSHR 1360/4885HTT 719/4885ALDH1A1 4683/4885 |
| US-20040059087-A1 | Peptide nucleic acids | RNGTT, POLM, POLRMT | TSHR 1360/4885HTT 719/4885ALDH1A1 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.